|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||603.00 - 628.75|
|52-week range||508.10 - 663.00|
|PE ratio (TTM)||35.75|
|Earnings date||8 Aug 2018|
|Forward dividend & yield||2.00 (0.32%)|
|1y target est||N/A|
Cipla Limited’s (NSE:CIPLA) announced its latest earnings update in March 2018, which indicated that the company gained from a robust tailwind, leading to a double-digit earnings growth of 40.16%. InvestorsRead More...
The company has received final approval for its abbreviated new drug application (ANDA) for Testosterone Cypionate injection in the strengths of 100mg/ml and 200mg/ml from the US Food and Drug Administration (USFDA), Cipla said in a filing to BSE.
The Mumbai-based firm has received final nod from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Efavirenz tablets in 600mg strength, Cipla said in a statement.
The company has received final approval from the United States Food and Drug Administration (USFDA) for its product which is a generic version of Hospira Inc's Isuprel injection, Cipla said in a statement.
The company has received final approval for its abbreviated new drug application (ANDA) for Isoproterenol hydrochloride injection USP, 0.2mg/mL, single - use sterile Ampoule from the United States Food and Drug Administration (USFDA).
Under this agreement, Lilly’s BASAGLAR that is manufactured by Lilly will be marketed and distributed in India by Cipla.
JM Financial is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 600 in its research report dated May 23, 2018.
Cipla Ltd, India's second-biggest drugmaker by market capitalization, posted a fourth-quarter profit on Tuesday, but missed street estimates. Net profit came in at 1.79 billion rupees for the quarter ended ...
Cipla is likely to report a net profit of Rs 356.7 crore in the fourth quarter of FY18, according to estimates of Reuters poll of analysts.
"Under this agreement, Cipla will get exclusive marketing rights for five years in India for critical limb ischemia due to atherosclerotic peripheral arterial disease (CLI-PAD) with Stempeutics manufacturing and supplying the product to Cipla," the company said in a statement.
Cipla enters into an agreement with MannKind Corporation to market inhaled insulin, Afrezza for diabetes patients.
Under the agreement, Cipla is responsible for obtaining regulatory approvals to distribute Afrezza in India, including approval from the Drug Controller General of India (DCGI), while MannKind will manufacture and supply the drug
Cipla has received final approval for its abbreviated new drug application (ANDA) for Phenylephrine Hydrochloride Injection USP, 50 mg/5 mL (10 mg/mL) and 100 mg/10 mL (10mg/mL) Pharmacy Bulk Package, Phenylephrine Hydrochloride Injection USP, 10 mg/mL SingleDose Vial and Exemestane Tablets, 25mg from the United States Food and Drug Administration (USFDA).
"The company is fairly valued at current market price. However, if Q4FY18 results are robust then we can expect a target of Rs 650 by FY19 end," says Akash Jain, Vice-president, Equity Research at Ajcon Global Services.
"The United States Food and Drug Administration (USFDA) conducted a routine current Good Manufacturing Practices (cGMP) audit at its Indore formulations facility from April 2, 2018 till April 13, 2018," Cipla said in a BSE filing.
The US Food and Drug Administration has recently completed its inspection of Cipla's Indore facility.
Cipla Ltd, India's fourth-largest drugmaker by revenue, said third-quarter net profit rose 7 percent on strong domestic sales, but fell short of analysts' estimates. Net profit attributable to shareholders ...
Indian private sector lenders Yes Bank Ltd and IndusInd Bank Ltd will join the BSE stock exchange's 30-member Sensex index, effective Dec. 18, the index provider said on Friday. Drugmakers Lupin Ltd and ...
Mumbai, Aug 14 (IANS) Broadly positive global cues, coupled with healthy buying in consumer durables, metals and automobile stocks, lifted the key Indian equity indices from their five-week lows to trade ...
Cipla Ltd, India's fourth-largest drugmaker by sales, reported a 20 percent rise in quarterly profit, beating analysts' estimates, as higher sales in Europe and South Africa offset weakness in its key domestic market. Revenue from South Africa, Cipla's third largest market, rose 21 percent to 4.88 billion rupees ($76.03 million) compared with last year while Europe revenues climbed 33 percent to 1.58 billion rupees. India revenues fell 13 percent to 12.71 billion rupees, impacted by a nationwide tax reform.